Transaction in Own Shares

Summary by AI BETAClose X

Fevertree Drinks plc has announced the purchase of 216,404 ordinary shares between July 6th and July 10th, 2026, as part of its share buyback program. The weighted average purchase price across these transactions was approximately 777.7 pence per share, with individual trades ranging from 745.00 pence to 817.00 pence. The company intends to cancel these repurchased shares.

Disclaimer*

Fevertree Drinks PLC
14 July 2026
 

14th July 2026                         

Fevertree Drinks plc

("Fever-Tree" or the "Company")

Transaction in Own Shares

 

Fevertree Drinks plc ("Fever-Tree" or the "Company") announces today it has, in accordance with the authority granted by shareholders at its 2025 Annual General Meeting held on 5th June, purchased the following number of ordinary shares of £0.0025 each in the Company (the "Ordinary Shares") through the Company's broker, Investec Bank plc ("Investec") in the period from 6th July to 10th July 2026.

Date

Venue

Volume-weighted average price (p)

Aggregated volume

Lowest price per share (p)

Highest price per share (p)

06 July 2026

XLON

789.4912

           31,421

782.0000

800.0000

07 July 2026

XLON

786.4751

           44,814

779.0000

817.0000

08 July 2026

XLON

780.2827

           29,276

760.5000

798.5000

08 July 2026

AIMX

781.7500

           15,000

781.7500

781.7500

09 July 2026

XLON

756.0002

           52,834

745.0000

766.5000

09 July 2026

AIMX

755.7500

             5,000

755.7500

755.7500

10 July 2026

XLON

775.0038

           52,660

766.0000

779.5000

 

The Company intends to cancel the purchased shares.

   

Schedule of Purchases - Individual Transactions

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law by virtue of the European Union (Withdrawal) Act 2018, as amended), a full breakdown of the individual trades made by Investec on behalf of the Company as part of the share buyback programme is attached to this announcement.

 

http://www.rns-pdf.londonstockexchange.com/rns/0849M_1-2026-7-13.pdf

 

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

 

For further information please contact:

 

Investor queries

Steve Nightingale, Director of Investor Relations I steve.nightingale@fever-tree.com I +44 (0)7951 849564

 

Media queries

Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0)770 332 9024  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings